Anika Therapeutics Inc. (ANIK)
NASDAQ: ANIKHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANIK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $177.22M
- Forward P/E
- 13.23
- EPS (TTM)
- -$0.03
- Dividend yield
- None
- 52-week range
- 9.01 – 22.88
- Day range
- 12.98 – 13.70
- Volume / Avg
- 166.48K / 105.68K
- Beta
- —
- Shares outstanding
- 13.40M
52-week range
ANIK stock today
On Nov 20, ANIK ended the session at $13.23, shedding $0.05 (0.38%), versus the S&P 500's 3.70% decline. Shares are 42.2% below their 52-week high of $22.88, set on Aug 10, 2026 and 46.8% above the 52-week low of $9.01, in the middle of the past year's range. ANIK is up 37.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 33.9%.
Anika Therapeutics has posted a net loss over the last twelve months (EPS of -$0.03), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Anika Therapeutics
Company profileAnika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Stephen D. Griffin
- Headquarters
- Bedford, MA
- Employees
- 235
- Website
- anika.com
Financial highlights
Full financialsIn fiscal 2025, Anika Therapeutics generated $112.8 million in revenue, down 5.9% from fiscal 2024, its first annual decline since 2024. Anika Therapeutics reported a net loss of $10.9 million, compared with a loss of $56.4 million a year earlier. Gross margin was 56.6% (down from 63.4%) and operating margin -9.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $112.82M | $119.91M | $120.79M | $113.83M | $147.79M |
| Growth | -5.91% | -0.73% | +6.12% | -22.98% | +13.29% |
| Net income | $-10.88M | $-56.38M | $-82.67M | $-14.86M | $4.13M |
| EPS (diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 |
Analyst forecast
ForecastConsensus (2 analysts)
strong_buy
Avg. price target
$20.00+51.17%
- Strong buy 1
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $-0.01 vs $0.02
- Surprise
- -150.00%
ANIK news
All ANIK news- Anika Therapeutics Q3 Revenue Rises 10%; Raises 2026 OutlookNasdaqANIK, BF.A
- Anika Therapeutics Reports Third Quarter 2026 Revenue of $30.6 millionNasdaqANIK, HEI.A
- Anika Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026GlobeNewswire
- Merck's Remigromig Meets Main Goal in Diabetic Macular Edema StudyNasdaqMRK, RGEN, ANIK, PGEN
- AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease StudyNasdaqAMGN, RGEN, ANIK, PGEN
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNasdaqNVS, RGEN, ANIK, IONS
- PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer BeginsNasdaqPBYI, RGEN, ANIK, PGEN
Anika Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| UTMDUtah Medical Products Inc. | 69.49 | -2.07% | $198.01M | vs ANIK |
| PDEXPro-Dex Inc. | 63.00 | -0.77% | $201.60M | vs ANIK |
| KTWOK2 Capital Acquisition Corporation Class A | 10.13 | 0.00% | $203.02M | vs ANIK |
| KRMDKORU Medical Systems Inc. | 3.19 | -7.27% | $138.37M | vs ANIK |
| CLPTClearPoint Neuro Inc. | 6.91 | -5.47% | $221.49M | vs ANIK |
| PYPDPolyPid Ltd. | 6.12 | -6.56% | $129.29M | vs ANIK |
| PROFProfound Medical Corp. | 6.38 | -3.19% | $233.68M | vs ANIK |
| STIMNeuronetics Inc. | 1.25 | +0.81% | $120.60M | vs ANIK |
Indexes, lists and sector
Anika Therapeutics stock FAQ
What is Anika Therapeutics's stock price today?
ANIK last traded at $13.23 as of Nov 20, 4:00 PM EST, down 0.38% on the day. Prices are delayed at least 15 minutes.
Who is Anika Therapeutics's CEO?
Mr. Stephen D. Griffin is the chief executive officer of Anika Therapeutics Inc., which has about 235 employees.
What is the ANIK 52-week high?
The 52-week high for ANIK is $22.88 and the 52-week low is $9.01. The stock is currently 42.2% below its high.